Group One Trading’s Citius Pharmaceuticals CTXR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-8
Closed -$100 – 7648
2024
Q3
$100 Buy
+8
New +$135 ﹤0.01% 6476
2024
Q1
– Sell
-148
Closed -$2.8K – 7181
2023
Q4
$2.8K Buy
148
+36
+32% +$683 ﹤0.01% 6720
2023
Q3
$1.92K Sell
112
-16
-13% -$380 ﹤0.01% 7054
2023
Q2
$3.84K Sell
128
-48
-27% -$1.58K ﹤0.01% 6831
2023
Q1
$5.15K Buy
176
+148
+529% +$4.27K ﹤0.01% 6268
2022
Q4
$553 Hold
28
– – ﹤0.01% 6932
2022
Q3
$1K Buy
+28
New +$770 ﹤0.01% 7283

Other funds holding CTXR

Group One Trading's CTXR Position: Q3 2026 in Review

Group One Trading reduced its Citius Pharmaceuticals (CTXR) stake by 31% in Q3 2026, selling an estimated $284 and leaving 1,070 shares worth $568. The position accounts for ﹤0.01% of the portfolio, ranked #7611.

Group One Trading first reported a position in CTXR in Q3 2022 and has held it in 13 quarters since. The position peaked at $57.2K in Q1 2023. 34 funds tracked by Wall St. Rank hold CTXR as of Q3 2026.

  • Group One Trading held 1,070 shares of Citius Pharmaceuticals worth $568 as of Q3 2026.
  • Group One Trading sold 481 Citius Pharmaceuticals shares in Q3 2026, an estimated $284.
  • Citius Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #7611 holding.
  • Group One Trading first reported a position in Citius Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Group One Trading's Citius Pharmaceuticals position peaked at $57.2K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.